Hyundai Pharm and Innovigen Bio Sign MOU for Joint ADC Research and Development

Strengthening ADC R&D Competitiveness

Hyundai Pharm announced on September 22 that it has signed a memorandum of understanding (MOU) with Innovigen Bio, a company specializing in the development of antibody-drug conjugate (ADC) therapeutics, for joint research and development of next-generation anticancer drugs.

Hyun Jongsu, CEO of Innovigen Bio (left), and Lee Sangjun, CEO of Hyundai Pharm (right), are posing for a commemorative photo. Hyundai Pharm

This agreement was established to strengthen the domestic competitiveness of ADC research and development and to build a collaborative framework for global market entry between Hyundai Pharm and Innovigen Bio.

Through this partnership, the two companies plan to closely cooperate throughout the entire research and development process, including the discovery of new drug candidates using innovative ADC platform technologies, joint preclinical and clinical development, and the establishment of global technology transfer and commercialization strategies.

Hyundai Pharm will lead the clinical and commercialization stages based on its years of accumulated pharmaceutical R&D capabilities and global network, while Innovigen Bio aims to expand its differentiated ADC pipeline by leveraging its proprietary antibody engineering and linker-payload technologies.

A representative from Hyundai Pharm stated, "This collaboration will serve as a pivotal turning point for securing ADC technology, which is gaining attention in the field of anticancer drugs," adding, "We will develop globally competitive and innovative new drugs by capitalizing on the strengths of both companies."

A representative from Innovigen Bio also commented, "Through this strategic partnership with Hyundai Pharm, we have established a foundation to translate our proprietary technologies into tangible new drug development," and added, "Through close cooperation between the two companies, we aim to achieve meaningful results on the global stage."

This content was produced with the assistance of AI translation services.